Geistlich Pharma Ag

Ed. Geistlich Sohne Ag Fur Chemische Industrie

Hanns Moehler

Thomas Mueller

Rolf Wilhelm Pfirrmann

H Paul Redmond

Ruediger Stendel

James C Costin

Paul H Redmond

A method of preventing, inhibiting or reducing cytokine release and the incidence of a cytokine release syndrome (CRS) or a cytokine storm in a subject with certain oxathiazin-like compounds and/or related compounds.

Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release

Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.

Processes for preparing oxathiazin-like compounds

Growing community of inventors

Maennedorf, Switzerland

Hanns Moehler